CONQUEST: Patient Impact
At this stage, the primary objective of CONQUEST is to rapidly evaluate potential treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD). Secondary objectives include global SSc outcomes, including some focused on skin and other aspects of the disease.
Learn more about CONQUEST.
This platform clinical trial is the first of its kind in rare autoimmune diseases.
The CONQUEST Steering Committee
Meet the people providing external oversight of CONQUEST.
CONQUEST in the News
Conquest has attracted broad attention from the lay and biopharma press due its impact and novelty. We are gratified by the coverage and look forward to educating our stakeholders about the opportunity.